Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 18 · Randomised trials: 1 · 2016–2025
Showing the 50 most relevant studies, sorted by most relevant.
Imran Ahmed, A. Boulton, S. Rizvi, et al.
BMJ Open, 2019
Lisa M. Weatherly, J. Gosse
Journal of toxicology and environmental health. Part B, Critical reviews, 2017
M. Yueh, R. Tukey
Annual review of pharmacology and toxicology, 2016
Bueno ALA, Aguzzoli NHG, Bonamigo RR
2025
- Dermatitis, Allergic Contact
- Allergens
- Patch Tests
BackgroundContact dermatitis is a common dermatosis in dermatology. The patch test is the gold standard for diagnosis, using a panel of common allergens and irritants. In Brazil, a standardized battery of 30 substances is used. However, comprehensive epidemiological data on contact dermatitis are limited, and no studies have compiled and compared nationwide results.ObjectivesThis study aimed to assess the positivity rate of patch tests using the Brazilian Standard Battery in suspected contact dermatitis cases from 2000 to 2022. We also evaluated associations between reactive substances and clinical and demographic variables and examined the variation in reactivity frequency to allergenic substances over the study period.MethodsA systematic literature review was conducted using PubMed, Scielo, and LILACS. We evaluated the prevalence of positive tests for each substance, examined associations between variables such as gender, region, and age, and assessed variations in patch test positivity over time.ResultsInitially, 55 articles were identified, and 10 were included in the review. Nickel sulfate was the most frequently positive allergen, while triclosan, P-tertiary buthyphenol, and anthraquinone were the least prevalent. Test positivity increased every 5-years for kathon CG, neomycin, and nickel sulfate, while it decreased for quaternion 15 and thimerosal.Study limitationsThe results were limited by the small number of articles included in the review.ConclusionsThis pioneering study in Brazil provides valuable insights for dermatological allergy practitioners into the prevalence of patch test positivity for each substance in the Brazilian Standard Battery, aiding in informed decision-making and patient management.
Abstract licence: CC BY
Zhi-lin Zhu, Su-chun Wang, Fei-fei Zhao, et al.
Environmental pollution, 2019
Ji Lu, Yue Wang, Jie Li, et al.
Environment international, 2018
Mohammad A. Alfhili, M. Lee
Oxidative Medicine and Cellular Longevity, 2019
Ji Lu, Min Jin, S. H. Nguyen, et al.
bioRxiv, 2018
Xiaolan Zhou, Dong Xu, Yuancai Chen, et al.
Chemical Engineering Journal, 2020
Xuhui Chen, Linda Mou, Jiayuan Qu, et al.
The Science of the Total Environment, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.